Navigation Links
Denosumab in Medical News

Amgen's Denosumab and Eli Lilly's Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018

Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that A...

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

...cial performance in 2009 and are focused on making denosumab a success," said Kevin Sharer, chairman and chief ...y driven by lower clinical trial costs for denosumab and Vectibix registrational studies, parti... of its pivotal, Phase 3, head-to-head study where denosumab demonstrated superiority versus Zometa((R)) (zoled...

Amgen Highlights Data to Be Presented at ASCO

...7 (Saturday, May 30, 2009, 4:15pm-4:30pm) denosumab Researchers will present data from the denosumab oncology development program, including an oral pr...ion of final Phase 2 data looking at the effect of denosumab on the treatment of giant cell tumor (GCT) of the ...

Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08

...e have made progress on our plans to commercialize denosumab for PMO. Also, we are looking forward to reviewing important data on pipeline products including denosumab in certain oncology indications and Vectibix in co...arily driven by lower clinical trial costs for the denosumab registrational studies due to completion of enroll...

Latest Osteoporosis Research Translated for Health Professionals to Use in Clinical Setting

... such as: Secondary Causes of Bone Loss; Bone Quality: New Imaging to Refine Fracture Risk and Improve Therapy; and Emerging Pharmaceutical Therapies: denosumab and New EAAs EVENT: 8th International Symposium on Osteoporosis: Translating Clinical Research Into Practice WHEN: April 1-5, 2009 FE...

24th Annual EAU Congress highlights many new developments

...ones. Dr. Smith from Boston (U.S.) is keen on presenting the exciting results of his trial (A randomized, double-blind, placebo-controlled trial of denosumab in men receiving androgen deprivation therapy for non-metastatic prostate cancer) from 10:25 to 10:55 hours as part of the 'The best EAU papers' sessi...

New Drug May Strengthen Women's Bones

... In study, denosumab outperformed a standard ,,osteoporosis therapy ... MONDAY, Oct. 27 (HealthDay News) -- The drug denosumab can boost bone mass in postmenopausal women, accor... 64, with low bone mass for more than one year. denosumab inhibits the activation of bone-resorbing cells ca...

Denosumab Reduces Bone Erosion

...ented at EULAR 2007, the Annual Treatment with denosumab 60 mg and 180 mg (with background methotrexate) re...trial, six and 12 months to assess the capacity of denosumab to reduce progression of RA associated bone erosio...al of denosumab, revealing that patients receiving denosumab experienced a reduced progression of erosions comp...

Doctors Hopeful for Elizabeth Edwards

...is may include drugs that block estrogen, if the tumor is fueled by that hormone, or chemotherapy. Looking to the future, a monoclonal antibody called denosumab is currently in clinical trials for use against both bone metastasis and osteoporosis, say scientists. While the treatments now available can onl...

Bone Density Can Be Beefed Up With Twice-a-year shots

...cording to a study, Amgen Inc.'s experimental drug denosumab taken twice a year can rejuvenate the density of b... It was observed that after a year of treatment, denosumab strengthened the bone density in the lumbar portio...t, those women who got a 60 milligram injection of denosumab every six months, showed the best result. Till dat...
Denosumab in Medical Technology

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

THOUSAND OAKS, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced positive top-line results from a pivotal Phase 3 head-to-head trial evaluating denosumab administered subcutaneously versus Zometa((R)) (zoledronic acid) administered as an intraveno...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatmen... outcome of this important study, which shows that denosumab can reduce or delay the serious complications of b...viewing the results from a second Phase 3 study of denosumab effects in advanced cancer patients later this yea...
Denosumab in Medical Dictionary

Osteoporosis

... symptoms to treatment options, find in-depth news and information to help cope with osteoporosis . ... Studies Positive on New Osteoporosis Drug denosumab ... Osteoporosis Q&A ... Osteoporosis (oss-tee-oh-puh-ro-sis) is a condition that means your bones are ... Osteoporosis in the vertebra...
Denosumab in Biological Technology

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

THOUSAND OAKS, Calif. and LONDON, July 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosi...

FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab

THOUSAND OAKS, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted Amgen's submission and filed a Biologics License Application (BLA) for denosumab, an investigational RANK Ligand inhibitor. Th...

Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August

... Advisory Committee to Review denosumab Data THOUSAND OAKS, Calif., June 22 /PRNewswi.... We look forward to discussing the data from our denosumab trials in these settings with the members of the C...ts, the incidence and types of adverse events with denosumab were similar to placebo. The most common adverse e...

Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55

...lso submitted an application in Canada for these indications. In the European Union, the Company has submitted an application for the approval of denosumab for treatment of PMO in women, and treatment of bone loss associated with hormone ablation therapy in patients with breast and prostate cancer. ...

Amgen Positioned to Deliver Attractive Growth Over Next Five Years

...s pipeline -- including the experimental bone drug denosumab -- growing in-line products and continuing to purs...ieve blockbuster status: Sensipar(R) (cinacalcet), denosumab for osteoporosis and denosumab for cancer-related indications." Roger M. Perlmu...

Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23

... and chief executive officer. "We are now focused on plans to commercialize denosumab in post-menopausal osteoporosis. We're excited about the opportunity to bri...r our emerging pipeline were offset by lower clinical trial costs for our denosumab registrational studies due to completion of enrollment and the benefit de...

New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment

... SAN ANTONIO, Dec. 15 /PRNewswire/ -- denosumab is a new drug being studied to prevent fractures i...therapy. Results of a phase 3 clinical trial using denosumab were presented Friday evening at the San Antonio B...llis, MD, from the Seattle Cancer Care Alliance. denosumab is a highly specific antibody that interrupts the ...
Other Tags
(Date:7/30/2015)... ... July 30, 2015 , ... Political unrest ... NGO’s, according to a new survey by leading international insurance provider Clements Worldwide. ... employee medical expenses represented the largest sources of financial losses among respondents. , ...
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year ... retinal implant, more commonly known as the “bionic eye,” researchers have determined the trial ... viable tool for patients facing or already affected by complete vision loss as a ...
(Date:7/30/2015)... Chicago, IL (PRWEB) , ... July 30, 2015 ... ... many patients are living longer and do not find a complete removable denture ... the standard of care. The practices that incorporate less expensive, immediate loading techniques ...
(Date:7/30/2015)... Orem, UT (PRWEB) , ... July 30, 2015 , ... When trying to gain weight, many people place a lot ... the amount of calories that need to be consumed. However, another key component to successful ... to gain weight. To assist with this, CB-1 Weight Gainer gives three tips on ...
(Date:7/30/2015)... ... July 30, 2015 , ... PeopleKeys, a company with over ... Stress: Train the Trainer” webinar. The webinar, the newest installment in their popular DISC ... , The Managing Stress: Train the Trainer webinar is intended for people interested in ...
Breaking Medicine News(10 mins):Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
Other Contents